BrainsWay Ltd. (NASDAQ:BWAY - Free Report) - Research analysts at HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for shares of BrainsWay in a note issued to investors on Wednesday, March 12th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $0.18 per share for the year, down from their previous forecast of $0.32. HC Wainwright has a "Buy" rating and a $16.00 price objective on the stock. The consensus estimate for BrainsWay's current full-year earnings is $0.08 per share.
BrainsWay Stock Performance
BrainsWay stock traded up $0.13 during mid-day trading on Monday, reaching $10.23. 20,101 shares of the company were exchanged, compared to its average volume of 74,856. BrainsWay has a twelve month low of $4.61 and a twelve month high of $11.79. The firm's 50-day simple moving average is $10.29 and its two-hundred day simple moving average is $9.66. The firm has a market cap of $192.68 million, a PE ratio of 101.22 and a beta of 1.29.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BWAY. Lazard Asset Management LLC bought a new stake in BrainsWay in the fourth quarter valued at about $44,000. JPMorgan Chase & Co. grew its holdings in BrainsWay by 316.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company's stock worth $136,000 after buying an additional 11,221 shares in the last quarter. Sei Investments Co. bought a new position in BrainsWay in the 4th quarter worth approximately $149,000. Cubist Systematic Strategies LLC grew its holdings in BrainsWay by 14.6% in the 4th quarter. Cubist Systematic Strategies LLC now owns 19,228 shares of the company's stock worth $181,000 after buying an additional 2,446 shares in the last quarter. Finally, Rhumbline Advisers boosted its stake in BrainsWay by 10.8% during the 4th quarter. Rhumbline Advisers now owns 21,966 shares of the company's stock valued at $207,000 after purchasing an additional 2,144 shares in the last quarter. Institutional investors and hedge funds own 30.11% of the company's stock.
BrainsWay Company Profile
(
Get Free Report)
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
Featured Articles
Before you consider BrainsWay, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BrainsWay wasn't on the list.
While BrainsWay currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
